Scientific Programme

Transcription

1 Scientific Programme Thursday, 4 October Registration ESU Course Clinical and histopathological basics and main research questions in prostate cancer Chair : M. Sedelaar, Nijmegen (NL) Faculty : A. Bjartell, Malmo (SE) S. Tyritzis, Athens (GR) European School of Urology: A unique possibility for urological education M. Sedelaar, Nijmegen (NL) Histopathological classification of prostate cancer a. TNM: S. Tyritzis, Athens (GR) b. Gleason Grading: M. Sedelaar, Nijmegen (NL) c. Histopathological subtypes: A. Bjartell, Malmo (SE) d. Molecular pathogenesis/molecular subtypes/molecular tests (SelectMDX, Prolaris, Decipher etc): S. Tyritzis, Athens (GR) Clinical basics and unmet needs in daily practice a. Introduction: M. Sedelaar, Nijmegen (NL) b. Diagnostics, prognosis, therapy i. Screening and staging: A. Bjartell, Malmo (SE) ii. Localized disease (active surveillance, surgery and radiotherapy options): S.Tyritzis, Athens (GR) iii. Metastasized disease: M. Sedelaar, Nijmegen (NL) Discussion Faculty Close Aims and objectives This course provides a full overview of pathological and clinical aspects of prostate cancer and areas that are still under debate or need more research. It will lead the trainee from the pathological assessment, staging and available genetic tests to screening, imaging, local- and systemic therapies for prostate cancer. At the end of the course the trainee should be familiar with the clinical management questions and treatment decisions of prostate cancer.

2 Opening Antonia Vlahou, Athens (GR) Kerstin Junker, Homburg (DE) Rodolfo Montironi, Ancona (IT) Meeting Chair ESUR Chair ESUP Chair Session 1 Epigenetic regulation and reprogramming Chairs: Carmen Jeronimo, Porto (PT) Hing Leung, Glasgow (GB) Neuroendocrine differentiation via epigenetic reprogramming Francesca Demichelis, Trento (IT) KDM6A mutation and NMIBC subtypes Margaret Knowles, Leeds (GB) Chromatin remodeling in renal cell carcinoma: The role of PBMR1, BAP1 and SETD2 Egbert Oosterwijk, Nijmegen (NL) Break Session 2 Data integration Resources and approaches Chairs: Gabri Van Der Pluijm, Leiden (NL) Antonia Vlahou, Athens (GR) Consolidating the system-level understanding of clinical pathologies through data integration and biomarker-aided rational interpretation Aristotelis Chatziioannou, Athens (GR) Mechanism-based biomarker/drug target discovery Leonidas Alexopoulos, Athens (GR) Short presentations O-1 Defining the proteomic subtypes of non muscle invasive bladder cancer Rafael Stroggilos, Athens (GR) O-2 Combining multi-parametric MRI and an epigenetic biomarker assay improves patient prostate cancer risk profile Yanti Setiasti, Nijmegen (NL) O-3 Discovery of an androgen responsive long non-coding RNA that associates with progression of ERG overexpressing prostate cancers Annika Kohvakka, Tampere (FI) O-4 Signaling contexts for utilizing the imipridone ONC201 in prostate cancer Francesca Amoroso, Belfast (GB)

3 Friday, 5 October Session 3 Cellular plasticity and cellular interaction Chairs: Zoran Culig, Innsbruck (AT) Kristin Tasken, Oslo (NO) Adipocytes and (prostate) cancer progression Catherine Muller-Staumont, Toulouse (FR) The Glucocorticoid receptor, a new target for improved ADT therapy? Martin Puhr, Innsbruck (AT) Impact of taxane chemotherapy and TGFbeta blockade on EMT to MET reversal in advanced prostate cancer model Natasha Kyprianou, Lexington (US) The microbiota: A new variable impacting cancer immunotherapy outcomes Lisa Derosa, Paris (FR) Short presentations O-5 Inhibition of Hedgehog signaling affects paracrine tumor-stroma communication and decreases tumor growth in castration resistant prostate cancer (CRPC) Britta Soderkvist, Umea (SE) O-6 Cancer-associated fibroblast heterogeneity within the prostate cancer stromal microenvironment Natalie Sampson, Innsbruck (AT) O-7 Patient-derived cancer-associated fibroblasts promote orthotopic tumor growth and metastatic spread in a prostate cancer xenograft model Johannes Linxweiler, Homburg (DE) Break Session 4 Networking in urological research Chairs: Isabel Heidegger, Innsbruck (AT) Guido Jenster, Rotterdam (NL) TRAIN - TRIBBLES Research and Innovation Network Endre Kiss-Toth, Sheffield (GB) TransPot Hing Leung, Glasgow (GB) YAU project presentation Evanguelos Xylinas, Paris (FR) The EAU Research Foundation Anders Bjartell, Malmo (SE) Lunch Poster session 1 Poster numbers P-1 P-30

4 Break Session 5 Point-counterpoint session: Molecular subtyping of MIBC Chairs: Yves Allory, Paris (FR) Alexandra Masson-Lecomte, Paris (FR) Molecular subtyping of MIBC: Molecular subclassification: The new consensus Markus Eckstein, Erlangen (DE) Do we need molecular subtypes in clinical practice? Gunter Niegisch, Dusseldorf (DE) Panel discussion Chair: Yves Allory, Paris (FR) Panel: Markus Eckstein, Erlangen (DE) Alexandra Masson-Lecomte, Paris (FR) Gunter Niegisch, Dusseldorf (DE) Short presentations 3 Chairs: Imran Ahmad, Glasgow (GB) Jocelyn Ceraline, Strasbourg (FR) O-8 Large cribriform growth pattern identifies cribriform Gleason score 3+4=7 prostate cancer patients at high risk for recurrence and metastasis Eva Hollemans, Rotterdam (NL) O-9 Network analysis of Prostate cancer-derived CWR22, LNCaP and VCAP xenografts for elucidation of the key regulators in castration resistance development Mario Cangiano, Leiden (NL) O-10 Toward the development of clinically relevant ex vivo models of prostate cancer Clementine Le Magnen, Basel (CH) O-11 Functional in vivo screening identifies micrornas driving metastatic dissemination of prostate cancer cells to different sites Yvonne Ceder, Lund (SE) O-12 Positive surgical margin assessment: comparison between digital and light microscopy measurement in radical prostatectomy specimens Alessia Cimadamore, Ancona (IT) O-13 Therapeutic reprogramming of the transcriptome of ERG-positive prostate cancers by epigenetic and transcriptional modulators Giuseppina Carbone, Bellinzona (CH) Dominique Chopin Lecture

5 Saturday, 6 October Session 6 Biomarkers and clinical trials Chairs: Mariangela Mancini, Padua (IT) Rodolfo Montironi, Ancona (IT) Biomarkers: Definition, requirements, pitfalls Thomas Keller, Leipzig (DE) Biomarker inclusion in urological cancer trials: Reality and visions Aristotelis Bamias, Athens (GR) Biomarkers for TKI response prediction in kidney cancer Annelies Verbiest, Leuven (BE) What can be the best biomarkers for response prediction in immunotherapy Elfriede Nossner, Munich (DE) Applied medical imaging - digital pathology approaches in new trials Holger Moch, Zurich (CH) Break Short presentations 4 Chairs: Natasha Kyprianou, Lexington (US) Martin Puhr, Innsbruck (AT) O-14 Multi-stage pathological and immunohistochemical characterization of N- butyl-n-(4-hydroxybutyl)-nitrosamine-induced murine bladder cancer Jacqueline Fontugne, Paris (FR) O-15 The epithelial-mesenchymal transition reversing microrna, mir-520f, sensitizes tumor cells for platinum-based chemotherapeutic drugs Gerald Verhaegh, Nijmegen (NL) O-16 Enzalutamide re-activates STAT3 in CRPC bone metastases Malin Hagberg Thulin, Umea (SE) O-17 Repurposing of mebendazole as a potential synergistic therapy with docetaxel in castration resistant prostate cancer Linda Rushworth, Glasgow (GB) O-18 Circulating micrornas as markers for prostate cancer detection and metastasis prediction Carmen Jeronimo, Porto (PT) Lunch Poster session 2 Poster numbers P-31 P56 and LB-1 to LB Break Session 7 Liquid biopsies Chairs: Kerstin Junker, Homburg (DE) Margaret Knowles, Leeds (GB) Bladder cancer; mutation/dna-methylation test Ellen Zwarthoff, Rotterdam (NL)

6 Urine proteomics Antonia Vlahou, Athens (GR) cfdna: Diagnostic/prognostic/predictive markers Emil Christensen, Aarhus (DK) Short presentations O-19 UroSEEK signature in invasive bladder cancer Marie-Lisa Eich, Birmingham (US) O-20 Cell-free DNA (c.f.d.n.a) recapitulates genomic profile of renal cell carcinoma (RCC) and corresponds to disease progression and therapy response Lewis Au, London (GB) ARTP Award and closing remarks